- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Diasome Pharmaceuticals, a clinical stage diabetes therapeutics company, announced today that four abstracts were accepted for publication at the 68th Annual Meeting of the American Diabetes Association, being held June 6 through June 10 at the Moscone Convention Center in San Francisco, Ca.
All of the abstracts highlight HDV-Insulin, the Company's proprietary oral and injectable insulin products. The following will be presented as posters from Saturday, June 7 through Monday, June 9 in Hall D:
* A 2-Week Randomized Active Comparator Study of Two HDV-Insulin Routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus. Sherwyn Schwartz, MD, Blair Geho, MD, PhD, Len Rosenberg, PhD, RPh, John Lau. Diabetes and Glandular Research Center, San Antonio, TX, and Diasome Pharmaceuticals, Conshohocken, PA.
* Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients with Type 2 Diabetes Mellitus. Sherwyn Schwartz, MD, Blair Geho, MD, PhD, Len Rosenberg, PhD, RPh, John Lau. Diabetes and Glandular Research Center, San Antonio, TX, and Diasome Pharmaceuticals, Conshohocken, PA.
* Hepatic-Directed Vesicle Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes. Blair Geho, MD, PhD, John Lau, Len Rosenberg, PhD, RPh, Diasome Pharmaceuticals, Conshohocken, PA.
In addition, presenters will be on hand Saturday, June 7, from 11:30 a.m. to 1:30 p.m., and on Monday, June 9, from noon to 2 p.m. for questions and discussions with attendees.
Diasome is developing Oral HDV-Insulin, a nanotechnology-based cell targeting system for the improved treatment of diabetes mellitus. Diasome's therapies have been tested in more than 100 subjects to date. The Company is preparing to conduct longer term clinical trials in 2008 after having held an end of Phase II meeting with the FDA in 2007.
About Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc. is a venture-backed biopharmaceutical company focused on novel insulin-based therapies for the improved treatment of diabetes. The Company was formed in 2004 and has completed multiple Phase II human studies of HDV-Insulin, its proprietary insulin targeting system. Diasome uses a unique, nano-technology based cell targeting system to preferentially deliver insulin to the hepatocytes in the liver. This technology has led to the development of Oral HDV-Insulin, an advanced oral delivery system for insulin. For more information, please visit Diasomeís website at www.Diasome.com.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nationís premier voluntary health organization supporting diabetes research, information and advocacy. Founded in 1940, the Association's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. The Associationís commitment to research is reflected through its scientific meetings; education and provider recognition programs; and its Research Foundation and Nationwide Research Program, which fund breakthrough studies looking into the cure, prevention, and treatment of diabetes and its complications. www.Diabetes.org
For more information, please click here
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016